Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Pacific Biomarkers CSO Elizabeth T. Leary Co-Authors Paper in March Issue of Clinical Chemistry

Published: Wednesday, March 09, 2011
Last Updated: Wednesday, March 09, 2011
Bookmark and Share
Article explores the contribution of assay methodologies in risk classification for cardiovascular disease.

Elizabeth T. Leary, PhD, Chief Scientific Officer at Pacific Biomarkers, Inc. (PBI), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has co-authored a paper appearing in the March issue of Clinical Chemistry. The article explores the contribution of assay methodologies in the risk score classification of cardiovascular disease.

In the paper, Dr. Leary and her co-authors evaluated the accuracy of cardiovascular disease risk score classification by direct LDL cholesterol, calculated LDL cholesterol, and non-HDL cholesterol compared to classification by reference measurement procedures performed at the Centers for Disease Control and Prevention.

A total of 175 individuals were examined, including 138 with cardiovascular disease or conditions that may affect measurement of LDL cholesterol.

The study concluded that except for individuals with elevated triglycerides, 7 of 8 direct LDL cholesterol methods failed to show improved cardiovascular disease risk score classification over the corresponding calculated LDL cholesterol methods.

Non-HDL cholesterol showed overall the best concordance with the reference measurement procedures for cardiovascular disease risk score classification of both normal and hypertriglyceridemic individuals.

"Most clinical papers pretty much ignore assay differences and their contribution in the interpretation of study findings," said Dr. Leary. "We have presented evidence that not all assays for cardiovascular risk are equally accurate, a conclusion that may help select the appropriate assay for each study and refine methodologies that target those patients at risk for cardiovascular disease."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pacific Biomarkers' Dr. Amar A. Sethi Recognized by R&D Directions as One of Nine "Most Notable People in R&D"
Vice President of R&D singled out for work in seeking clues to heart-disease risk.
Thursday, March 03, 2011
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos